Spermosens Signs Collaboration Deal with Genea for Planned Clinical Study of Fertility Diagnostic

MT Newswires · 3d ago
05:35 AM EST, 11/09/2026 (MT Newswires) -- Spermosens (SPERM.ST) signed a collaboration agreement with Australian fertility group Genea to conduct an independent clinical study of its JUNO-Checked diagnostic in in-vitro fertilization cycles. The prospective study will assess whether JUNO-Checked results are associated with fertilization outcomes in consenting IVF patients, the medical device products company said Monday. Spermosens will supply the diagnostic equipment, sensors, and software, while Genea will provide the clinical and research infrastructure. The study is expected to start after approval from the Human Research Ethics Committee, anticipated in mid-2027. It would be conducted at one or more of Genea's Australian clinics, subject to ethics approval and a separate study agreement. It would be the first time JUNO-Checked is evaluated by an external clinic group.